Grip strength tests gene therapy for aging
Your hand grip strength reveals more about your health than most people realize. Now it is being used to measure something unprecedented: whether gene therapy genuinely improves the aging body.
A small number of clinics outside the US and Europe already offer gene therapy as an anti-aging treatment. They use viruses called AAV vectors to deliver genes into muscle or brain cells. The genes vary: follistatin for muscle growth, VEGF for blood vessel formation, and genes such as SIRT1 associated with cellular maintenance. Triple Helix Science is one of the companies behind these therapies.
The report describes how grip strength is being used to assess the effects of those therapies. Grip strength has long been recognized as a biomarker of biological age: large meta-analyses involving hundreds of thousands of participants show that its link to mortality is comparable to that of systolic blood pressure. But how reliable is that measurement when someone is also undergoing a targeted intervention?
The problem of biomarker decoupling
That is precisely the issue this report addresses. A biomarker that works well during normal aging may not hold up when a targeted intervention is introduced. If follistatin makes muscles stronger, grip strength rises. But does that mean biological age has actually decreased? Or does it only reflect the direct effect of the therapy itself?
The authors describe this as biomarker decoupling: the measurement and the underlying aging process can diverge once an intervention targets a specific mechanism. That makes evaluating anti-aging therapies fundamentally harder than previously assumed.
Outside regulation, but rich in data
What makes this report notable is its context. These therapies take place outside standard clinical research. Published data is scarce. Yet this community is accumulating practical experience at a scale mainstream science has not yet reached. For longevity science, that is a double-edged situation: it produces relevant observations, but without the controls of a randomized trial, conclusions remain preliminary.
Grip strength remains a useful measure. But this report shows we need to think more carefully about what we are actually measuring when the body undergoes multiple interventions at once.
Want to research this yourself?
Search for example:
- grip strength biological age | AAV gene therapy aging | biomarker decoupling anti-aging